The study found a 70% improvement in brown spots after four weeks of using AlumierMD’s Prep & Enhance: Discolouration collection.
A new, albeit small, clinical study has positively assessed the efficacy of AlumierMD’s medical-grade skincare for treating discolouration.
The research examined the collective effect of the four products within AlumierMD’s Prep & Enhance: Discolouration collection, looking at the range’s effectiveness in both stabilising and improving redness and discolouration before an in-clinic treatment.
It was designed to show how the products could help prepare skin for, and enhance the safety and clinical outcomes of, in-clinic treatments by improving skin quality and resilience in patients of Fitzpatrick types I-VI.
The small study was conducted with 24 patients of Fitzpatrick Types I-VI, including four men and 19 women, aged from their 20s to 60s, over four weeks. It was a multi-country and multi-site study, which included both subjective patient satisfaction data capture and analysis of surface and subsurface skin conditions using IntelliFlash®, cross-polarized and UV lighting.
The patients’ skin was first cleansed using AlumierMD’s Purifying Gel Cleanser before patients were placed into a VISIA imaging device. This process was repeated four weeks later after patients had added AlumierMD’s Prep & Enhance: Discolouration to their existing skincare routines, without the addition of any other products, or changes to their normal daily activities.
Indices analysed were spots, UV damage, wrinkle depth, brown spots, texture, redness, pores and porphyrins. Over the course of the study, the clinical team observed and quantified improvement in skin texture, redness, UV and brown spots, as well as an overall reduction in TruSkinAge®.
Specifically, after four weeks, the clinical team found a 70% improvement in brown spots, 58% improvement in redness, 58% improvement in pores, 54% improvement in wrinkles, and 45% improvement in skin texture.
These results would indicate an improvement in skin quality and resilience, which may suggest more predictable post-treatment outcomes and hopefully a reduced risk of undesirable effects including post-inflammatory hyperpigmentation.
The overall reduction in spots, texture, pores and UV and brown spots also coincides with decades of scientific literature that evidence the efficacy of physical sunscreen, non-hydroquinone brightening agents, retinol and L-ascorbic acid when formulated at clinically validated concentrations.
“This subjectively and objectively quantified, in-clinic trial established that both redness and brown spots can be significantly reduced in patients of broad Fitzpatrick types within just four weeks by using a medical-grade, at-home topical skincare collection for discolouration”, explains Dr David Ecclelstone, founder of MediZen, who one of three aesthetic experts associated with the study.
“It is well recognised that patients seeking in-clinic treatments from an aesthetic-medicine practitioner are at risk of potential undesirable effects, post-inflammatory hyperpigmentation and increased downtime, as well as limited clinical outcomes, if the skin is inflamed and/or melanocytes are excessively triggered,” Dr Ecclelstone continued. “As practitioners, we need to feel confident recommending pre-treatment skincare and in-clinic treatments for pigmentation for all Fitzpatrick types.”
The AlumierMD Prep & Enhance: Discolouration collection contains four products, including the award-winning vitamin C serum, EverActive C&E + Peptide; Retinol Resurfacing Serum 0.5%; Clear Shield Broad Spectrum Sunscreen SPF 42; and the arbutin and kojic acid-containing brightening serum, Intellibright Complex.
AlumierMD is a multi-award-winning medical-grade skincare company and a finalist in the 2022 Aesthetic Awards as Best Topical Skincare brand.
